Binds Specifically-identified Oligosaccharide Structure Patents (Class 424/137.1)
  • Patent number: 10259888
    Abstract: A compound comprising one or more polysaccharide moieties each independently represented by the formula ?(1?4)-[GlcNH—R]n-2,5-anhydromannose, wherein n is a positive integer from 3 to 500, and R is H or an acyl group, is described. The compound can be manufactured by (a) reacting chitosan with an acylating agent sufficient to partially N-acylate the chitosan, yielding a modified chitin/chitosan mixed polymer; and (b) reacting the modified chitin/chitosan mixed polymer with a deaminating agent to cleave the mixed polymer at the unacylated chitosan moieties. The compound can be used to immunize against fungal infection. Antibodies specific to the compound, and the use of such antibodies to protect against fungal infection are also described.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: April 16, 2019
    Assignee: Wellstat Vaccines, LLC
    Inventors: Francis Michon, Samuel J. Wohlstadter, Frank Comer, Kuishu Ren
  • Patent number: 10087242
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: October 2, 2018
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DESCARTES
    Inventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
  • Patent number: 9873741
    Abstract: There is disclosed compositions and methods relating to or derived from anti-TIM3 antibodies. More specifically, there is disclosed fully human antibodies that bind TIM3, TIM3-antibody binding fragments and derivatives of such antibodies, and TIM3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 23, 2018
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou, Irina Krapf
  • Patent number: 9556270
    Abstract: Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: January 31, 2017
    Assignees: KYOWA HAKKO KIRIN CO., LTD, KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION
    Inventors: Shin-ichiro Takayanagi, Hitomi Tomura, Tomonori Tawara, Yoshimasa Inagaki, Tsuguo Kubota, Koichi Akashi, Yoshikane Kikushige
  • Patent number: 9409976
    Abstract: The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative- and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: August 9, 2016
    Assignee: IGM BIOSCIENCES, INC.
    Inventors: Nelson N. H. Teng, Neelima M. Bhat, Marcia M. Bieber, Bruce A. Keyt
  • Patent number: 9315566
    Abstract: Described herein are antigen binding proteins that bind to pathogenic mycobacteria-derived Mannose-Capped Lipoarabinomannan (ManLAM) and methods and kits for using and making the antigen binding proteins. Also described herein are antigen binding proteins that bind to the alpha 1-2 linkage mannose caps of ManLAM, antigen binding proteins that bind to a mannose cap with up to three alpha 1-2 linked mannose residues, and antigen binding proteins that bind to LAM with a mannose sugar capping motif.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: April 19, 2016
    Assignees: National University of Singapore, DSO National Laboratories
    Inventors: Paul Anthony Macary, Conrad En Zuo Chan, Brendon John Hanson, Markus R. Wenk
  • Publication number: 20150147328
    Abstract: The present invention relates to a vaccine composition for preventing staphylococcus aureus infection containing, as an active ingredient, a ribitol-phosphate which has been modified only by a ?-configuration in N-Acetylglucosamine (GlcNAc), a repeating unit of the ribitol-phosphate, or a wall teichoic acid (WTA) containing the repeating unit. The composition according to the present invention contains a coupling motif (an epitope) for an anti-WTA antibody, and thus can be effectively used as a vaccine composition or to prevent staphylococcus aureus infection by generating anti-WTA antibody.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 28, 2015
    Applicants: MOGAM BIOTECHNOLOGY INSTITUTE, PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION
    Inventors: Bok Luel Lee, Kurokawa Kenji, Dong-Jun Jung, Jang-Hyun An, Yu-Jin Jeon, Na Hyang Kim, Takahashi Kazue, Eunmi Kim, Dong Ho Ahn
  • Patent number: 9040049
    Abstract: The present invention relates to antibodies and antigen-binding fragments thereof, immunogenic peptide(s), and siRNA molecules which are capable of inhibiting neovascularization and/or angiogenesis and endothelial cell proliferation. The invention relates to antibodies and antigen-binding fragments thereof with specificity towards the metalloprotease domain of ADAM 15 and to immunogenic peptide(s) that elicits such antibodies. The invention also relates to compositions and kits comprising the antibodies and immunogenic peptide(s) of the invention, as well as methods and uses of the antibodies and antigen-binding fragments thereof and immunogenic peptide(s), as well as siRNA molecules.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: May 26, 2015
    Assignee: Vasgen Limited
    Inventors: Salman Rahman, Yatin Patel, Holger Gerhardt, Andrea Emma Lundkvist
  • Publication number: 20150139998
    Abstract: The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.
    Type: Application
    Filed: March 4, 2013
    Publication date: May 21, 2015
    Inventors: Johannes Huebner, Otto Holst, Christian Theilacker, Karolina Kruszynska, Stefan Geiss-Liebisch, Agnieszka Beczala
  • Publication number: 20150132295
    Abstract: This document provides methods and materials related to genetic variations associated with endometriosis. For example, this document provides methods for using such genetic variations to assess risk of, or susceptibility of developing or diagnosing endometriosis.
    Type: Application
    Filed: November 11, 2014
    Publication date: May 14, 2015
    Inventors: ELI HATCHWELL, PEGGY S. EIS
  • Publication number: 20150125451
    Abstract: This disclosure describes, in one aspect, a composition that includes a ?-glucan component and an antibody component that specifically binds to the ?-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to ?-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of ?-glucan and administering to the subject a composition that comprises a ?-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 7, 2015
    Applicant: Biothera, Inc.
    Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
  • Publication number: 20150110790
    Abstract: A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 23, 2015
    Applicants: Glenveigh Pharmaceuticals, LLC, CDA Royalty Investors, LLC
    Inventors: Charles David Adair, Yuping Wang
  • Publication number: 20150110785
    Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion
  • Publication number: 20150110781
    Abstract: The present disclosure relates generally to anti-rabies antibodies that can bind to and neutralize rabies virus. Antibodies of the present technology are useful alone or in combination with therapies known in the art for the treatment or prevention of rabies infection.
    Type: Application
    Filed: May 24, 2012
    Publication date: April 23, 2015
    Inventors: Enyun Shen, Shiqi Ren
  • Publication number: 20150093388
    Abstract: The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 2, 2015
    Applicant: ImmunoGen, Inc.
    Inventors: Olga AB, Daniel Tavares, Julianto Setiady, Sharron Ladd, Christina N. Carrigan, Lingyun Rui
  • Publication number: 20150086555
    Abstract: The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Inventors: Ole Olsen, Christina L. Boozer
  • Publication number: 20150071854
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 12, 2015
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
  • Patent number: 8975233
    Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: March 10, 2015
    Assignee: Northwind Medical, Inc.
    Inventors: Emily A. Stein, Kondapavulur T. Venkateswara-Rao, Michael A. Evans
  • Publication number: 20150056134
    Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against Sialyl-Lewisa (sLea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to sLea. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.
    Type: Application
    Filed: August 26, 2014
    Publication date: February 26, 2015
    Inventors: Ritsuko SAWADA, Shu-Man SUN, Wolfgang SCHOLZ
  • Publication number: 20150056205
    Abstract: This invention relates generally to methods of treating inflammatory bowel diseases (IBD), asthma, Crohn's Disease (CD), multiple sclerosis (MS), rheumatoid arthritis (RA), graft versus host disease (GVHD), host versus graft disease, and various spondyloarthropathies, comprising administering a steroid-sparing effective amount of an immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.
    Type: Application
    Filed: July 28, 2014
    Publication date: February 26, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Ivan LIEBERBURG
  • Publication number: 20150050282
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Application
    Filed: June 20, 2014
    Publication date: February 19, 2015
    Applicants: INSTITUT PASTEUR, Centre National De La Recherche Scientifique, Universite Paris Descartes
    Inventors: Laurence MULARD, Julien BOUTET, Catherine GUERREIRO, Farida NATO, Philippe SANSONETTI, Armelle PHALIPON
  • Publication number: 20150044218
    Abstract: The present disclosure provides immunogenic compositions comprising the N-domain of carcinoembryonic antigen (CEA). These compositions are useful for inducing or enhancing an immune response, for inhibiting tumor cell growth and for treating cancer.
    Type: Application
    Filed: August 18, 2014
    Publication date: February 12, 2015
    Inventors: Aws Abdul-Wahid, Jean Gariépy
  • Publication number: 20150023968
    Abstract: An isolated DNA molecule comprising a fragment of the gene encoding the feline NIS is disclosed as well as methods of use thereof. Also provided are methods for rational diet design of food composition suitable for administration to feline companion animals afflicted with hyperthyroidism, comprising (a) accessing at least one database that comprises a first data set relating functional gene profile of a biofluid or tissue sample from an animal to physiological condition of the animal, where the functional gene profile is that of the feline NIS gene; (b) accessing at least one database that comprises a second data set relating effects of bioactive dietary components on the functional gene profile; (c) using an algorithm drawing on these data sets, processing input data defining physiological condition to derive a nutritional formula promoting wellness of a feline companion animal afflicted with hyperthyroidism; and (d) preparing a food composition based on the nutritional formula.
    Type: Application
    Filed: December 6, 2012
    Publication date: January 22, 2015
    Inventors: Samer Al-Murrani, Jeffrey Brockman
  • Publication number: 20140363436
    Abstract: Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 11, 2014
    Inventors: Hitoshi Suzuki, Run Fan, Bruce A. Julian, Jan Novak, Zina Moldoveanu, Zhixin Zhang, Milan Tomana, Jiri Mestecky, Robert J. Wyatt, Yasuhiko Tomino, Yusuke Suzuki, Stephen Olson
  • Publication number: 20140363437
    Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 11, 2014
    Inventors: Yair Reisner, Esther Bachar-Lustig
  • Publication number: 20140356367
    Abstract: The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Zhongwu Guo, Qianli Wang, Shouchu Tang
  • Publication number: 20140356415
    Abstract: The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are also useful for treatment and prevention of disease in a subject such as cancer.
    Type: Application
    Filed: June 3, 2014
    Publication date: December 4, 2014
    Applicants: University of Maryland, College Park, University of Maryland, Baltimore
    Inventors: Philip R. DeShong, Lenea Stocker, Daniel C. Stein, Stefanie N. Vogel, Katharina Richard
  • Publication number: 20140341908
    Abstract: The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems.
    Type: Application
    Filed: May 20, 2014
    Publication date: November 20, 2014
    Applicant: INSTITUTE FOR SYSTEMS BIOLOGY
    Inventors: Carrie M. ROSENBERGER, Alan ADEREM
  • Publication number: 20140341909
    Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.
    Type: Application
    Filed: June 27, 2014
    Publication date: November 20, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventor: Vince Pozsgay
  • Publication number: 20140328847
    Abstract: It has now been discovered that mice with an ablated galectin-12 gene exhibit enhanced fat mobilization (lipolysis), have reduced adipose tissue mass, improved insulin sensitivity and glucose tolerance, and increased mitochondrial respiration. Inhibition of galectin-12 activity can therefore be used to reduce, mitigate, inhibit and/or prevent obesity, type 2 diabetes, metabolic diseases, mitochondrial diseases, other disease conditions associated with and/or caused by the abnormal expression or overexpression of galectin-12, and other disease conditions with normal galectin-12 expression but will benefit from galectin-12 inhibition.
    Type: Application
    Filed: October 2, 2012
    Publication date: November 6, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ri-Yao Yang, Fu-Tong Liu, Lan Yu, Daniel K. Hsu
  • Publication number: 20140314742
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: October 15, 2013
    Publication date: October 23, 2014
    Applicant: TRACON PHARMACEUTICALS, INC.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Publication number: 20140294930
    Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.
    Type: Application
    Filed: August 3, 2012
    Publication date: October 2, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Victor Nizet, Nina van Sorge
  • Publication number: 20140294840
    Abstract: Provided are human miRNAs associated with the generation of immunological tolerance during pregnancy as well as fragments, derivatives and variants thereof for use in immunomodulation. Said miRNAs may be used in diagnosis and treatment of disorders associated with a deregulated immune response, autoimmune disorders, pregnancy associated diseases, failure or problems of placentation and complications resulting from allotransplantations. In addition, new pharmaceutical and diagnostic compositions for use in diagnosis and therapy of said disorders are described.
    Type: Application
    Filed: November 30, 2012
    Publication date: October 2, 2014
    Inventors: Jorn Bullerdiek, Inga Flor
  • Publication number: 20140255409
    Abstract: A method for extracorporeal elimination of one or more components from blood where whole blood or blood plasma is added to a blood treatment device containing an adsorbent which binds the one or more components is disclosed. The adsorbent comprises at least one matrix to which at least one ligand having specific binding affinity to said one or more component is covalently bound. The ligand comprises a glycosidically bound aglycon and at least one saccharide, preferably blood group determinant A, blood group determinant B, blood group H determinant, a P antigen, or a Pk antigen; or said ligand is an amino acid, a peptide or an antibody. Methods for treatment of transplant recipients, and to use a blood treatment device is also disclosed.
    Type: Application
    Filed: October 29, 2012
    Publication date: September 11, 2014
    Inventor: Kurt Nilsson
  • Patent number: 8815239
    Abstract: The present invention relates to compounds derived from sugars which reproduce the epitopes of Shigella flexneri serotypes 3a and X and to the use thereof for the preparation of vaccine compositions. More specifically, the subject matter of the present invention relates to novel glycoconjugated compounds comprising oligosaccharides or polysaccharides described hereinafter, to the method for synthesizing these oligosaccharides or polysaccharides and glycoconjugates, to derivatives of these oligosaccharides or polysaccharides, to compositions containing same, and also to the use of the glycoconjugates for vaccination purposes. Finally, the present invention relates to methods for diagnosing a Shigella flexneri infection using one or more oligosaccharides or polysaccharides or conjugates thereof.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: August 26, 2014
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Universite Paris Descartes
    Inventors: Laurence Mulard, Julien Boutet, Catherine Guerreiro, Farida Nato, Philippe Sansonetti, Armelle Phalipon
  • Publication number: 20140234318
    Abstract: The present invention describes oligosaccharide sequences, which are specifically expressed by human tumors. The present invention is related to a method of determining an oligosaccharide sequence, which comprises a tumor specific terminal N-acetylglucosamine residue, in a biological sample, the presence of said sequence in said sample being an indication of the presence of cancer. The present invention provides antigenic substances comprising said oligosaccharide sequences in a polyvalent form and it further provides diagnostic agents, pharmaceutical compositions and cancer vaccines comprising said oligosaccharide sequences or substances binding to said oligosaccharide sequences. The present invention is also related to methods for the treatment of cancer.
    Type: Application
    Filed: March 24, 2014
    Publication date: August 21, 2014
    Applicant: GLYKOS FINLAND OY
    Inventors: Jari NATUNEN, Susann TENEBERG, Karl-Anders KARLSSON, Tero SATOMAA, Annamari HEISKANEN
  • Patent number: 8808698
    Abstract: The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In preferred embodiments, the present invention utilizes agents that inhibit the specific binding of integrin alpha4beta1 (?4?1, VLA-4) to one or more of its ligands. The invention further relates to methods for screening test compounds for their ability to inhibit undesirable lymphangiogenesis and/or tumor metastasis.
    Type: Grant
    Filed: February 5, 2007
    Date of Patent: August 19, 2014
    Assignee: The Regents of the University of California
    Inventors: Judith Varner, Barbara Garmy-Susini
  • Publication number: 20140220003
    Abstract: The present invention relates to a therapeutic method and a diagnostic method using an antibody that binds to a ganglioside GM2 antigen, and a therapeutic agent and a diagnostic agent comprising as an active ingredient an antibody that binds to a ganglioside GM2 antigen. According to the present invention, the prognosis of GM2 positive mesothelioma patients can be improved by diagnosing and treating GM2 positive mesothelioma patients with a diagnostic agent and a therapeutic agent that comprise an anti-ganglioside GM2 antibody as an active ingredient.
    Type: Application
    Filed: December 5, 2013
    Publication date: August 7, 2014
    Applicants: KYOWA HAKKO KIRIN CO., LTD, NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY
    Inventors: Seiji YANO, Yusuke MACHINO, Yui SUZUKI
  • Publication number: 20140193416
    Abstract: The invention relates to a synthetic oligosaccharide representing part of the repeating unit of the Clostridium difficile glycopolymer PS-I and having the sequence of the pentasaccharide a-L-Rhap-(1?3)-?-D-Glcp-(1?4)-[a-L-Rhap-(1?3]-a-D-Glcp-(1?2)-a-D-Glcp or a synthetic fragment or derivative thereof. Preferably, the claimed synthetic oligosaccharide bears at least one linker L for conjugation to a carrier protein or for immobilization on a surface. Further aspects of the invention relate to advantageous methods for synthesizing said synthetic oligosaccharide and oligosaccharide-protein conjugate as well as to uses thereof, in particular as vaccines and diagnostic tools.
    Type: Application
    Filed: July 30, 2012
    Publication date: July 10, 2014
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, Christopher E. Martin, Felix Broecker, Chakkumkal Anish
  • Publication number: 20140178365
    Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.
    Type: Application
    Filed: October 10, 2013
    Publication date: June 26, 2014
    Applicant: SIALIX INC
    Inventors: Darius Ghaderi, Ana Paula Galvao da Silva, Jeffrey Behrens, Julie Hermann, Nancy Hurtado-Ziola
  • Patent number: 8758753
    Abstract: The present invention is related to the obtaining of modified antibodies by means of DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3), produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026, and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10), produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specifically binding the antigen of the original antibodies, but being at the same time less immunogenic.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: June 24, 2014
    Assignee: Centro de Inmunologia Molecular (CIM)
    Inventors: Cristina Maria Mateo De Acosta Del Rio, Josefa Lombardero Valladares, Lourdes Tatiana Roque Navarro, Alejandro Lopez Requena
  • Publication number: 20140170150
    Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.
    Type: Application
    Filed: February 11, 2011
    Publication date: June 19, 2014
    Applicant: The Governors of the University of Alberta
    Inventors: Christine SZYMANSKI, Harald NOTHAFT
  • Publication number: 20140170151
    Abstract: The present invention synthetic oligo-?-(1?6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-?-(1?6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-?-(1?6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-?-(1?6)-glucosamines, such as Staphylococcus aureus.
    Type: Application
    Filed: February 11, 2014
    Publication date: June 19, 2014
    Inventors: A. Stewart CAMPBELL, Obadiah J. PLANTE
  • Publication number: 20140161793
    Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.
    Type: Application
    Filed: December 14, 2011
    Publication date: June 12, 2014
    Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche Scientifique
    Inventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
  • Publication number: 20140161806
    Abstract: A specific antibody against a compound of formula (I) wherein X is O, NH, S, CH2; L is a linker that is a divalent spacer; A is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker L presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier A is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier A is a metallic nanoparticle; wherein the carrier/adjuvant A can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 12, 2014
    Applicant: AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (Italian Hospital)
    Inventors: Cristina Nativi, Lucio Toma, Barbara Richichi, Carlotta Lunghi
  • Publication number: 20140154257
    Abstract: Present invention is directed to materials and methods useful in diagnosing gut derived advanced glycation end-products (“Fru-AGEs”) associated with asthma, juvenile arthritis and other pro-inflammatory chronic diseases. Fru-AGEs arise from the interaction [fructosylation] between elevated gastro-intestinal excess free fructose and other food/bio-molecules including peptides, proteins, lipids, lipo/glycoproteins and others in the digestive tract. Such Fru-AGEs may further interact with moieties of the systemic circulation of those at risk [fructose malabsorbers], i.e. with acute phase proteins, heat shock proteins, immunoglobulins, esRAGE, and sRAGE. Specification describes methods to identify and/or make such excess-free-fructose derived immunogens, i.e.
    Type: Application
    Filed: June 3, 2013
    Publication date: June 5, 2014
    Inventor: Luanne Robalo DeChristopher
  • Patent number: 8703129
    Abstract: Disclosed herein are antibodies or antigen-binding portions thereof directed against extended Type I chain antigens, in particular extended Type I chain glycosphingolipids, and the uses of the antibodies or antigen-binding portions thereof in the diagnosis, amelioration, treatment or prevention of diseases or disorders in mammals, including humans, resulting from or associated with the improper activity/metabolism or the presence of extended Type I chain antigens, in particular extended Type I chain glycosphingolipids.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: April 22, 2014
    Assignee: GlycoNex, Inc.
    Inventors: Tong-Hsuan Chang, Jerry Ting, Mei-Chin Yang, Liahng-Yirn Liu, Shu-Yen Chang, Chia-Hao Chang
  • Patent number: 8697069
    Abstract: The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: April 15, 2014
    Assignees: Dana-Farber Cancer Institute, The Brigham and Women's Hospital, Inc.
    Inventors: Vijay K. Kuchroo, Laurent Monney, Jason L. Gaglia, Edward A. Greenfield, Gordon J. Freeman, Hanspeter Waldner
  • Publication number: 20140093504
    Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.
    Type: Application
    Filed: January 31, 2012
    Publication date: April 3, 2014
    Applicant: Her Majesty The Queen In Right Of Canada, as repre sented by the Minister of National Defence
    Inventors: Wei-Gang Hu, Laurel M Negrych, Damon Chau, Junfei YIN, Scott J. Jager, John W. Cherwonogrodzky
  • Publication number: 20140086923
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Application
    Filed: March 29, 2012
    Publication date: March 27, 2014
    Applicants: INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, INSERM (Institut National de la Sante et de la Recherche Medicale, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD - LYON 1
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive